Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal Melanoma.

Cancers·2026
Same author

Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.

Cell death & disease·2026
Same author

Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.

PloS one·2026
Same author

A large positive hysteresis effect for scene categories.

Journal of experimental psychology. Human perception and performance·2026
Same author

Establishing a tumor-specific center to enhance multidisciplinary cancer care in a general hospital: A model for clinical quality and innovation.

Cancer treatment and research communications·2026
Same author

NDV-GT wth hyperacute rejection in cancer therapy.

Virus research·2026
Same journal

Gene Therapy Briefs.

Human gene therapy. Clinical development·2019
Same journal

The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain.

Human gene therapy. Clinical development·2019
Same journal

Inhibition of miR-203 Ameliorates Osteoarthritis Cartilage Degradation in the Postmenopausal Rat Model: Involvement of Estrogen Receptor α.

Human gene therapy. Clinical development·2019
Same journal

Looking into a Crystal Ball: An Interview with Ron Crystal.

Human gene therapy. Clinical development·2019
Same journal

Gene Therapy Briefs.

Human gene therapy. Clinical development·2019
Same journal

Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases.

Human gene therapy. Clinical development·2019
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.6K

MiR-625-5p Inhibits Cardiac Hypertrophy Through Targeting STAT3 and CaMKII.

Kefeng Cai1, Huiqin Chen2

  • 1Cardiovascular Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou City, China.

Human Gene Therapy. Clinical Development
|October 17, 2019
PubMed
Summary
This summary is machine-generated.

MicroRNA-625-5p inhibits cardiac hypertrophy by targeting both STAT3 and CaMKII. This finding identifies miR-625-5p as a potential therapeutic target for preventing heart failure.

Keywords:
CaMKIISTAT3cardiac hypertrophymiR-625-5p

More Related Videos

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K
Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

8.0K

Related Experiment Videos

Last Updated: Jan 5, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.6K
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K
Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

8.0K

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Epigenetics

Background:

  • Cardiac hypertrophy is an adaptive response to cardiac stress, but sustained hypertrophy increases heart failure risk.
  • Calcium/calmodulin-dependent protein kinase II (CaMKII) is a key regulator of cardiac hypertrophy, yet its precise mechanism is not fully understood.
  • Signal transducer and activator of transcription 3 (STAT3) is implicated in cardiac hypertrophy.

Purpose of the Study:

  • To elucidate the regulatory mechanism of CaMKII in cardiac hypertrophy.
  • To investigate the role of microRNA-625-5p (miR-625-5p) in cardiac hypertrophy.
  • To explore the interplay between miR-625-5p, STAT3, and CaMKII in cardiac hypertrophy.

Main Methods:

  • Validation of CaMKII upregulation in cardiac hypertrophy models (in vivo and in vitro).
  • Assessment of CaMKII knockdown effects on Angiotensin II (Ang II)-induced cardiac hypertrophy.
  • Analysis of STAT3 expression and its role in CaMKII transactivation.
  • Prediction and confirmation of miR-625-5p targeting of STAT3 and CaMKII using TargetScan and experimental validation.
  • Rescue assays to evaluate the functional impact of miR-625-5p on Ang II-induced cardiac hypertrophy via the CaMKII/STAT3 pathway.

Main Results:

  • CaMKII was found to be upregulated in cardiac hypertrophy models.
  • Knockdown of CaMKII attenuated Ang II-induced cardiac hypertrophy.
  • STAT3 was highly expressed and stimulated CaMKII transactivation.
  • miR-625-5p was identified to target and inhibit both STAT3 and CaMKII.
  • miR-625-5p significantly attenuated Ang II-induced cardiac hypertrophy, mediated through the CaMKII/STAT3 pathway.

Conclusions:

  • miR-625-5p acts as a novel negative regulator of cardiac hypertrophy.
  • The study elucidates a mechanism where miR-625-5p inhibits cardiac hypertrophy by targeting both STAT3 and CaMKII.
  • These findings suggest miR-625-5p as a potential therapeutic target for preventing or treating cardiac hypertrophy and subsequent heart failure.